FEATURED

AACR 2016 Complete Coverage

Check out our complete coverage of the American Association for Cancer Research 2016 meeting in New Orleans.

ELCC 2016 Complete Coverage

Check out our complete coverage of the European Lung Cancer Conference 2016 meeting in Geneva.

Updated 2016 NCCN Guidelines for MM

Several new regimen options for the treatment of as well as the recently FDA-approved combination drug regimens are among the changes made.

Rising Incidence of AKI Following Nephrectomy

Acute kidney injury incidence after radical nephrectomy and partial nephrectomy is increasing.

Impact of Lifestyle on Colorectal Cancer

The link between lifestyle and colorectal cancer has been increasingly studied, highlighting the potential impact of the standard American diet and inactivity.

FDA Approves Second Biosimilar, Despite Concerns

Ongoing litigation over patent protection and concern about drug labeling guidance and potential safety issues have slowed the availability of biosimilars.

New NCCN Guidelines for Melanoma

A record number of new agents have been approved in the treatment of melanoma in the past 5 years.

Promising Secondary Endpoints for Ponatinib

The EPIC trial of ponatinib vs imatinib for chronic myeloid leukemia terminated early due to a high risk of arterial events.

Joe Biden Discusses Barriers to Research

Vice President Joe Biden said that improved data sharing, recruiting more patients into clinical trials, and streamlining the research grants process are needed to win the war on cancer.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Viewpoints

VP Joe Biden Discusses Barriers to Cancer Research at AACR Annual Meeting

VP Joe Biden Discusses Barriers to Cancer Research at AACR Annual Meeting

Vice President Joe Biden said that improved data sharing, recruiting more patients into clinical trials, and streamlining the research grants process are needed to win the war on cancer.

Sunitinib and Sorafenib May Not Prevent Recurrence Following Resection in High-risk, Non-metastatic RCC

Sunitinib and Sorafenib May Not Prevent Recurrence Following Resection in High-risk, Non-metastatic RCC

Adjuvant treatment with sorafenib or sunitinib are no more effective than a placebo in preventing recurrence in patients with advanced RRC following surgery.

Feature Articles

Study Suggests Rising Incidence of Acute Kidney Injury Following RN and PN

Study Suggests Rising Incidence of Acute Kidney Injury Following RN and PN

Acute kidney injury incidence after radical nephrectomy and partial nephrectomy is increasing.

The Impact of Lifestyle on Colorectal Cancer

The Impact of Lifestyle on Colorectal Cancer

The link between lifestyle and colorectal cancer has been increasingly studied, highlighting the potential impact of the standard American diet and inactivity.

Updated 2016 NCCN Guidelines in Oncology for Multiple Myeloma Highlight Significant Changes in Clinical Practice

Updated 2016 NCCN Guidelines in Oncology for Multiple Myeloma Highlight Significant Changes in Clinical Practice

Several new regimen options for the treatment of as well as the recently FDA-approved combination drug regimens are among the changes made.

FDA Approves Second Biosimilar Since Releasing Labeling Guidance, Despite Patent Protection, Safety Concerns

FDA Approves Second Biosimilar Since Releasing Labeling Guidance, Despite Patent Protection, Safety Concerns

Ongoing litigation over patent protection and concern about drug labeling guidance and potential safety issues have slowed the availability of biosimilars.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters